The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered

The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered

Bibliographic Details
Main Authors: Peter Borchmann, Alexander Fosså, Monika Długosz-Danecka, Boris Böll, Markus Dietlein, Carsten Kobe, Helen Goergen, Andreas Engert
Format: Article
Language:English
Published: Wolters Kluwer 2018-06-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000052

Internet

http://journals.lww.com/10.1097/HS9.0000000000000052

Similar Items